Heterogeneity in response to GLP-1 receptor agonists in type 2 diabetes in real-world clinical practice: insights from the DPV register – an IMI-SOPHIA study
Authors' conclusion
There is significant heterogeneity in responses to GLP-1 RA therapy among individuals with type 2 diabetes in routine clinical practice. However, in our study a substantial proportion achieved a reduction in either body weight or HbA1c. Future studies should explore why some individuals achieve either weight loss or HbA1c reduction but not both.
Study context
- Population
- Adults with T2D initiating liraglutide, semaglutide or dulaglutide, DPV registry
- Participants
- 4,467 adults
- Outcome
- Changes in HbA1c and body weight; response categories: HbA1c reduction only, weight loss only, both or neither
- Follow-up
- 6 months
Methodological detailsreal-world clinical practice, part of the IMI-SOPHIA project
- Real-world clinical practice
- Part of the IMI-SOPHIA project
Main finding
As reported in the abstract
- Median absolute HbA1c reduction, mmol/mol (IQR)
- 5.3 (13.9, −1.0)
- Median absolute HbA1c reduction, % (IQR)
- 0.49% [1.27, −0.09]
- Median relative body weight reduction (IQR)
- 1.43% (4.26, 0)
- Meaningful reduction in both HbA1c (≥5.5 mmol/mol [0.5%]) and body weight (≥5%)
- 14%
- HbA1c-only response
- 36%
- Weight-only response
- 7%
Observational data: associations, not effects.
Further findings
Predictors of response
- Men and higher baseline HbA1c more likely HbA1c-only response
- both p<0.001
- Older age and longer DM duration more likely weight-only response
- both p<0.001
- Higher baseline body weight and lower eGFR correlated with greater weight reduction
- both p<0.05
- Lower baseline HbA1c and longer DM duration linked to smaller HbA1c reductions
- both p<0.001
Original publication
Heterogeneity in response to GLP-1 receptor agonists in type 2 diabetes in real-world clinical practice: insights from the DPV register – an IMI-SOPHIA study. Diabetologia. Published 22 May 2025. doi:10. 1007/ s00125-025-06448-w
Composed by AI from the published abstract and checked against it. How Briefs are made →